Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Gilead Sciences Inc (GILD)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 97,005,120
  • Shares Outstanding, K 1,296,340
  • Annual Sales, $ 26,107 M
  • Annual Income, $ 4,628 M
  • 36-Month Beta 1.02
  • Price/Sales 3.72
  • Price/Cash Flow 7.78
  • Price/Book 4.46

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 20 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 1.54
  • Number of Estimates 8
  • High Estimate 1.71
  • Low Estimate 1.46
  • Prior Year 2.23
  • Growth Rate Est. (year over year) -30.94%

Price Performance

See More
Period Period Low Period High Performance
1-Month
71.49 +5.62%
on 09/07/18
76.59 -1.41%
on 08/31/18
+2.19 (+2.99%)
since 08/21/18
3-Month
68.60 +10.07%
on 06/27/18
79.04 -4.47%
on 07/26/18
+3.99 (+5.58%)
since 06/21/18
52-Week
64.27 +17.49%
on 05/03/18
89.54 -15.67%
on 01/29/18
-7.11 (-8.61%)
since 09/21/17

Most Recent Stories

More News
FDA Confirms Positive Safety Profile of Acadia's Nuplazid

Acadia's shares soar more than 20% as the FDA issues a statement reaffirming the positive benefit-risk profile of Nuplazid for patients with Parkinson's disease psychosis.

LGND : 259.84 (+0.80%)
GILD : 75.51 (+0.91%)
ACAD : 20.17 (+5.55%)
REGN : 390.28 (+0.78%)
SmarTrend Watching for Potential Pullback in Shares of Gilead Sciences After 1.04% Gain

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $74.75 to a high of $75.70. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of...

GILD : 75.51 (+0.91%)
Gilead Sciences Rises 1.04% on Heavy Volume: Watch For Potential Pullback

Gilead Sciences (NASDAQ:GILD) traded in a range yesterday that spanned from a low of $74.75 to a high of $75.70. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of...

GILD : 75.51 (+0.91%)
Next Resistance Level for Gilead Sciences (GILD) is $75.66

Gilead Sciences (NASDAQ:GILD) has opened bullishly above the pivot of $74.54 today and has reached the first level of resistance at $75.25. Should the shares continue to rise, the resistance pivots of...

GILD : 75.51 (+0.91%)
Exelixis' Partner Ipsen Gets Approval for Cabometyx in Canada

Exelixis (EXEL) and partner Ipsen Biopharmaceuticals Canada gain approval for Cabometyx from Health Canada for the treatment of advanced renal cell carcinoma in adult patients.

BAYRY : 22.5000 (+0.04%)
NVS : 85.46 (-0.59%)
EXEL : 16.76 (-0.77%)
GILD : 75.51 (+0.91%)
Ultragenyx's Shares Surge More Than 80% in the Year So Far

Ultragenyx's (RARE) share price has increased by about 85.2% year to date based on some positive developments for the product candidates of the company.

BAYRY : 22.5000 (+0.04%)
LGND : 259.84 (+0.80%)
RARE : 84.87 (-1.65%)
GILD : 75.51 (+0.91%)
Molecular Templates Surges 50%, Inks Cancer Deal With Takeda

Molecular Templates (MTEM) signs a collaborative contract with Japan's Takeda for jointly developing CD38-targeted engineered toxin antibodies to treat multiple myeloma. The stock soars past 50%.

GILD : 75.51 (+0.91%)
MTEM : 5.52 (-4.66%)
PCRX : 50.50 (-2.88%)
BSTC : 58.52 (+1.35%)
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Celgene, Sanofi and Gilead Sciences

CELG : 87.72 (-0.66%)
GILD : 75.51 (+0.91%)
REGN : 390.28 (+0.78%)
SNY : 43.55 (-1.36%)
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know

In the latest trading session, Gilead Sciences (GILD) closed at $73.88, marking a +0.31% move from the previous day.

GILD : 75.51 (+0.91%)
Biotech Stock Roundup: CELG, REGN Present Data, VKTX Soars on Drug's Success

Pipeline updates and data read-outs at the 27th European Academy of Dermatology and Venereology (EADV) Congress in France comprise some of the key developments in the biotech sector this week.

VKTX : 18.20 (-4.06%)
CELG : 87.72 (-0.66%)
GILD : 75.51 (+0.91%)
REGN : 390.28 (+0.78%)
SNY : 43.55 (-1.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade GILD with:

Business Summary

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The Company strive to transform and simplify care for people with life-threatening illnesses around the world. Gilead's portfolio of products...

See More

Key Turning Points

2nd Resistance Point 76.58
1st Resistance Point 76.04
Last Price 75.51
1st Support Level 74.86
2nd Support Level 74.22

See More

52-Week High 89.54
Fibonacci 61.8% 79.89
Fibonacci 50% 76.90
Last Price 75.51
Fibonacci 38.2% 73.92
52-Week Low 64.27

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar